Supreme Court Hears Oral Arguments on Reverse Payments to Generic Drug Manufacturers
FTC v. Actavis, Inc.
By Suzanne Van Arsdale – Edited by Jennifer Wong
On Monday, March 25, the Supreme Court heard oral arguments in FTC v. Actavis, Inc., to determine the legality, under antitrust laws, of patent litigation settlements made by the maker of a brand-name drug to the maker of a generic competitor to keep the generic off the market temporarily, known as a “reverse payment agreement” or “pay for delay.”
Read More...



